Episode 73. ASCO and EHA 2026 Lymphoma Roundu...

Topics Covered1. KOMET-007 and SNDX-5613-0708: Menin Inhibitors with Intensive ChemotherapyKOMET-007: Phase 1a/b study adding ziftomenib 600 mg once daily, starting on day 8, to 7+3 induction and continuing it through consolidation, in 99 patients with newly diagnosed NPM1-mutate ...  Show more

Blood Cancer Talks — Show NotesEpisode: Best of ASCO/EHA 2026 — Multiple Myeloma & AL AmyloidosisGuest: Dr. Prashant Kapoor, MD Professor of Medicine, Mayo Clinic, Rochester, MN Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo ClinicEpisode OverviewIn this episode, the ...  Show more

Send us Fan MailNinja Nerds,Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we dive deep into Lymphoma, breaking down its pathogenesis, clinical presentation, and the latest advancements in treatment. We explore the key differences between Hodgkin and Non-Ho ...  Show more

Join us for this captivating interview with our guest Prof Stefano Luminari, MD, PhD, from the University of Modena and Reggio Emilia in Italy, as he explores what precision medicine means today for follicular lymphoma. Together with our host Dr. Isabel Olivera-Martinez, they dis ...  Show more

This week, we continue our conversation about DLBCL, this time focusing our attention on the management of early stage disease.

In this week’s episode, we delve into the management of advance ...

Join us for a discussion with Prof Paolo Ghia, MD, PhD, from Università Vita Salute San Raffaele, Milan (Italy), as he explores how precision medicine is transforming CLL treatment. In this episode, discover how precision medicine is used daily in CLL to decide the best managemen ...  Show more